CN111388529B - 一种治疗灰指甲的药物组合物及其制备方法 - Google Patents
一种治疗灰指甲的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN111388529B CN111388529B CN202010205271.6A CN202010205271A CN111388529B CN 111388529 B CN111388529 B CN 111388529B CN 202010205271 A CN202010205271 A CN 202010205271A CN 111388529 B CN111388529 B CN 111388529B
- Authority
- CN
- China
- Prior art keywords
- parts
- fibrauretine
- pharmaceutical composition
- weight
- treating onychomycosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010195 Onychomycosis Diseases 0.000 title claims abstract description 49
- 201000005882 tinea unguium Diseases 0.000 title claims abstract description 49
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 26
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 26
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 26
- 235000009120 camo Nutrition 0.000 claims abstract description 26
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 26
- 239000011487 hemp Substances 0.000 claims abstract description 26
- 235000010298 natamycin Nutrition 0.000 claims abstract description 24
- 239000004311 natamycin Substances 0.000 claims abstract description 24
- 229960003255 natamycin Drugs 0.000 claims abstract description 24
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims abstract description 24
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 18
- 239000012043 crude product Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 241000123862 Fibraurea recisa Species 0.000 claims description 4
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 claims description 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 3
- 229950011318 cannabidiol Drugs 0.000 claims description 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 3
- RIDQRIPSFYHEGL-UHFFFAOYSA-N fibrauretin Natural products CC12CC=C3C(=O)OC(CC3(C)C1C(=O)C=CC2=O)c4cocc4 RIDQRIPSFYHEGL-UHFFFAOYSA-N 0.000 claims description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
- 229960004242 dronabinol Drugs 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 241000218236 Cannabis Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 15
- 241000233866 Fungi Species 0.000 abstract description 10
- 241001480043 Arthrodermataceae Species 0.000 abstract description 6
- 230000037304 dermatophytes Effects 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 230000002147 killing effect Effects 0.000 abstract description 4
- 206010034016 Paronychia Diseases 0.000 abstract description 3
- 241000029132 Paronychia Species 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010012442 Dermatitis contact Diseases 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 208000010247 contact dermatitis Diseases 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 210000000282 nail Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 4
- 229960002722 terbinafine Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- 241000223229 Trichophyton rubrum Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960002206 bifonazole Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- LDZSKLOBVMBMRH-UHFFFAOYSA-N 2-benzyl-1H-pyrrole 1,1'-biphenyl Chemical compound C(C1=CC=CC=C1)C=1NC=CC1.C1(=CC=CC=C1)C1=CC=CC=C1 LDZSKLOBVMBMRH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药制备技术领域,公开一种治疗灰指甲的药物组合物及其制备方法,该药物组合物包括如下重量份的原料:工业大麻提取物5‑10份,黄藤素10‑20份,5%碘酊35‑50份,纳他霉素0.01‑0.05份。本发明药物组合物中在5%碘酊的基础上添加特定比例的工业大麻提取物、黄藤素和纳他霉素,碘酊治疗灰指甲的作用得到充分体现,与工业大麻提取物、黄藤素和纳他霉素结合使用,对不同皮肤真菌有不同程度的抑制及杀灭作用,对致甲癣真菌达到强效杀菌、抑制复发并达到修复指甲。本发明药物组合物为外用制剂,直接作用在病菌部位,作用效果强,毒副作用小,剂型温和,使用方便,克服了碘酊对皮肤的刺激感,避免引起接触性皮炎和化学性甲沟炎。
Description
技术领域
本发明涉及医药制备技术领域,具体地说,是涉及一种治疗灰指甲的药物组合物及其制备方法。
背景技术
灰指甲,学名甲癣,是由皮癣菌、酵母菌及非皮癣菌等真菌侵犯甲板或甲下皮肤所引起的疾病。灰指甲的症状类型有5种:白色表浅型灰指甲、近端甲下型灰指甲、远侧端甲下型灰指甲、慢性甲沟炎型灰指甲、全甲营养不良型灰指甲。导致灰指甲的原因很多,主要是甲真菌感染指甲引起的,包括皮肤癣菌、酵母菌和霉菌,因缺少维生素及微量元素,导致指甲营养不良,无法有效抵制真菌侵入,真菌首先感染指甲周围的皮肤,然后通过指甲或趾甲的生长演变,逐渐侵入甲板内,并进一步生长和繁殖,直到破坏整个甲板。患者指(趾)甲变薄,浑浊,变形,易碎,甲表面失去光泽,粗糙,常有纵嵴及甲剥离,真菌镜检阴性。
甲癣病是一种难治愈的病,目前,在治疗上,有口服药和外用药两类,口服抗真菌药物,如特比萘芬片、伊曲康唑、氟康唑,可治愈80%以上的甲癣及甲真菌病。但因为这类药必须达到真菌所寄生的甲板处才能发挥抗菌作用,用药量大,用药时间长,且对肝脏有一定伤害。外用药西药类有复方苯甲酸软膏、咪康唑霜剂、复方雷锁辛制剂等,这类药物有杀皮肤真菌作用,但药物刺激性强,有难以忍受的疼痛而且治标不治本,复发率高。临床用于治疗更倾向于使用外用药。但是用于真菌感染很难治愈,效果差,容易复发,并且用于还有非真菌感染,因此单纯使用杀真菌的药物很难能够取得满意的疗效。因此需要研究一种见效快、安全可靠的治愈灰指甲的药物。
发明内容
本发明的目的在于解决上述问题,提供一种见效快、安全可靠的治疗灰指甲的药物组合物及其制备方法。
为了解决上述问题,本发明提供如下技术方案:
一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物5-10份,黄藤素10-20份,5%碘酊35-50份,纳他霉素0.01-0.05份。
优选的,一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物6-10份,黄藤素15-20份,5%碘酊40-50份,纳他霉素0.03-0.05份。
优选的,一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物8份,黄藤素15份,5%碘酊45份,纳他霉素0.03份。
优选的,所述工业大麻提取物中大麻二酚的含量>50%,所述四氢大麻酚的含量<0.3%。
优选的,所述黄藤素的纯度>90%。
优选的,所述黄藤素通过如下方法制备所得:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉6-8重量倍的85%乙醇中,水浴加热下超声浸提,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣6-8重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液2-4.5倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品5-7重量倍的65%-80%甲醇中,煎煮0.5-1.5h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣5-7重量倍的65%-80%甲醇中,煎煮0.5-1.5h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为8-15℃下结晶,过滤,干燥,即得到所述黄藤素。
优选的,步骤(1)所述超声频率为550-650W,温度为50-55℃,时间为10-20min。
本发明还提供一种治疗灰指甲的药物组合物的制备方法,其特征在于,按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
本发明治疗灰指甲的药物组合物为外涂药剂,不可食用,使用前先用温水洗手或洗脚,再用棉签沾此药剂涂抹灰指甲患处,每日早晚2次。
与现有技术相比,本发明具有以下有益效果:
(1)本发明药物组合物中添加工业大麻提取物、黄藤素和纳他霉素,工业大麻提取物中含有大麻二酚,具有杀菌、消炎、止痒、止痛上具有很好的效果,对于各类细菌、真菌具有广谱的杀菌能力;黄藤素采用纯中药黄藤进行提取,纯天然,纯度达到90%以上,具有广谱抑菌抗病毒作用、明显增加白细胞吞噬细菌的多重药理作用、良好的抗炎和增强机体免疫力作用,对真菌有抑制作用,尤其是对白色念球菌、石膏样毛菌、裴氏着色菌作用较强;纳他霉素是一种由链霉菌发酵产生的天然抗真菌化合物,可以广泛有效的抑制各种霉菌、真菌、酵母菌的生长,又能抑制真菌毒素的产生。
(2)本发明药物组合物中在5%碘酊的基础上添加特定比例的工业大麻提取物、黄藤素和纳他霉素,碘酊治疗灰指甲的作用得到充分体现,与工业大麻提取物、黄藤素和纳他霉素结合使用,对不同皮肤真菌有不同程度的抑制及杀灭作用,对致甲癣真菌达到强效杀菌、抑制复发并达到修复指甲。
(3)本发明药物组合物为外用制剂,直接作用在病菌部位,作用效果强,毒副作用小,剂型温和,使用方便,克服了碘酊对皮肤的刺激感,避免引起接触性皮炎和化学性甲沟炎。
具体实施方式
下面结合实施例对本发明作进一步说明,本发明的实施方式包括但不限于下列实施例。
实施例1
一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物5份,黄藤素10份,5%碘酊35份,纳他霉素0.01份。
一种治疗灰指甲的药物组合物的制备方法,包括如下步骤:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉6重量倍的85%乙醇中,水浴加热50℃,在550W超声功率下超声浸提20min,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣6重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液2倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品5重量倍的65%甲醇中,煎煮0.5h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣5重量倍的65%甲醇中,煎煮0.5h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为8℃下结晶,过滤,干燥,即得到所述黄藤素;
(7)按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
实施例2
一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物8份,黄藤素15份,5%碘酊45份,纳他霉素0.03份。
一种治疗灰指甲的药物组合物的制备方法,包括如下步骤:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉7重量倍的85%乙醇中,水浴加热52℃,在580W超声功率下超声浸提16min,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣7重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液3倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品6重量倍的70%甲醇中,煎煮0.8h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣6重量倍的70%甲醇中,煎煮0.8h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为10℃下结晶,过滤,干燥,即得到所述黄藤素;
(7)按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
实施例3
一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物6份,黄藤素15份,5%碘酊40份,纳他霉素0.03份。
一种治疗灰指甲的药物组合物的制备方法,包括如下步骤:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉8重量倍的85%乙醇中,水浴加热55℃,在600W超声功率下超声浸提12min,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣8重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液3.5倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品6重量倍的75%甲醇中,煎煮1h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣6重量倍的75%甲醇中,煎煮1h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为12℃下结晶,过滤,干燥,即得到所述黄藤素;
(7)按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
实施例4
一种治疗灰指甲的药物组合物,包括如下重量份的原料:工业大麻提取物10份,黄藤素20份,5%碘酊50份,纳他霉素0.05份。
一种治疗灰指甲的药物组合物的制备方法,包括如下步骤:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉8重量倍的85%乙醇中,水浴加热55℃,在650W超声功率下超声浸提10min,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣8重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液4.5倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品7重量倍的80%甲醇中,煎煮1.5h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣7重量倍的80%甲醇中,煎煮1.5h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为15℃下结晶,过滤,干燥,即得到所述黄藤素;
(7)按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
对比例1
配方中不添加工业大麻提取物,其他与实施例2相同。
对比例2
配方中不添加黄藤素,其他与实施例2相同。
对比例3
配方中不添加纳他霉素,其他与实施例2相同。
对照实验
1.抑菌和杀菌作用:
实验分为8组,即分为对照组、对比组和实施例组,对照组为无菌水,培养基为改良沙氏葡萄糖琼脂,选用酵母菌、红色毛癣菌、须癣毛癣菌、絮状表皮癣菌4种常见致灰指甲真菌。具体方法为先将菌液与琼脂培养基注入平面皿,混合待凝,用无菌打孔器在琼脂培养皿上打直径为6mm的孔6个,挑出孔内琼脂,然后滴入经过稀释2倍的中药组合物,每一孔约0.2ml,在25度条件下培养24h,观察抑菌圈的大小及真菌的活性的影响如表1,结果显示实验组对酵母菌、红色毛癣菌、须癣毛癣菌、絮状表皮癣菌4种皮肤致病真菌均有很强的抑菌和杀菌作用。
表1各组抑菌效果
2.治疗疗效
将实施例1-4的样品、对比例1-3样品及市售特比萘芬乳膏、联苯苄唑溶液剂治疗灰指甲药效进行对比。对180名灰指甲患者随机分组,每组20人;治疗方法:把溶液剂或乳膏外敷在灰指甲上,用纱布或创口贴覆盖,每日换药1-2次,治疗期间停止其他任何治疗。1个月后观察其疗效,结果见表2。
疗效判之标准:①痊愈:病甲消失,新指甲大部分长出,无瘙痒;②有效:部分指甲长出,变脆好转,未见与甲床分离,无蛀空,无瘙痒;③无效:用药后症状较治疗前无明显变化。
表2各组考察结果
样品 | 治愈/人 | 有效/人 | 无效/人 | 总有效率/% |
实施例1 | 16 | 4 | 0 | 100 |
实施例2 | 18 | 2 | 0 | 100 |
实施例3 | 16 | 4 | 0 | 100 |
实施例4 | 17 | 3 | 0 | 100 |
对比例1 | 13 | 6 | 2 | 90 |
对比例2 | 14 | 5 | 2 | 90 |
对比例3 | 15 | 4 | 1 | 95 |
特比萘芬 | 11 | 4 | 5 | 75 |
联苯苄唑 | 12 | 5 | 3 | 85 |
实验结果表明,实施例1-4用药药效要优于本发明对比例1-3,说明本发明配方药效最佳,同时本发明效果优于特比萘芬乳膏、联苯苄唑溶液剂。
综上所述,本发明制备的药物组合物可直达病变部位,消肿止痛,止痒杀虫、抗菌抗炎,拔毒生肌、活血解毒,治疗灰指甲效果较好,且刺激性小,无复发。
按照上述实施例,便可很好地实现本发明。值得说明的是,基于上述结构设计的前提下,为解决同样的技术问题,即使在本发明上做出的一些无实质性的改动或润色,所采用的技术方案的实质仍然与本发明一样,故其也应当在本发明的保护范围内。
Claims (8)
1.一种治疗灰指甲的药物组合物,其特征在于,由如下重量份的原料组成:工业大麻提取物5-10份,黄藤素10-20份,5%碘酊35-50份,纳他霉素0.01-0.05份。
2.根据权利要求1所述的治疗灰指甲的药物组合物,其特征在于,由如下重量份的原料组成:工业大麻提取物6-10份,黄藤素15-20份,5%碘酊40-50份,纳他霉素0.03-0.05份。
3.根据权利要求1所述的治疗灰指甲的药物组合物,其特征在于,由如下重量份的原料组成:工业大麻提取物8份,黄藤素15份,5%碘酊45份,纳他霉素0.03份。
4.根据权利要求1-3任一项所述的治疗灰指甲的药物组合物,其特征在于,所述工业大麻提取物中大麻二酚的含量>50%,四氢大麻酚的含量<0.3%。
5.根据权利要求1-3任一项所述的治疗灰指甲的药物组合物,其特征在于,所述黄藤素的纯度>90%。
6.根据权利要求5所述的治疗灰指甲的药物组合物,其特征在于,所述黄藤素通过如下方法制备所得:
(1)将黄藤粉碎过筛得黄藤粉;将黄藤粉加入至所述黄藤粉6-8重量倍的85%乙醇中,水浴加热下超声浸提,过滤得第一滤渣和第一滤液;
(2)将步骤(1)所得第一滤渣加入至所述第一滤渣6-8重量倍的75%甲醇中,水浴加热下超声浸提,过滤得第二滤渣和第二滤液;
(3)将第一滤液和第二滤液合并减压浓缩得到药液,采用于药液2-4.5倍体积的水搅拌溶解,采用无水乙酸乙酯溶剂进行萃取2-3次,继续用无水乙酸乙酯进行2-3次结晶处理,制得黄藤素粗品;
(4)将黄藤素粗品加入至黄藤素粗品5-7重量倍的65%-80%甲醇中,煎煮0.5-1.5h,通过活性炭脱色除杂,过滤后得到一次精提取液和一次粗品滤渣;
(5)将一次粗品滤渣加入至一次粗品滤渣5-7重量倍的65%-80%甲醇中,煎煮0.5-1.5h,得到二次精提取液;
(6)将一次精提取液和二次精提取液减压浓缩后,在温度为8-15℃下结晶,过滤,干燥,即得到所述黄藤素。
7.根据权利要求6所述的治疗灰指甲的药物组合物,其特征在于,步骤(1)所述超声频率为550-650W,温度为50-55℃,时间为10-20min。
8.一种权利要求1所述的治疗灰指甲的药物组合物的制备方法,其特征在于,按重量份将工业大麻提取物、黄藤素、5%碘酊、纳他霉素混合均匀即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010205271.6A CN111388529B (zh) | 2020-03-23 | 2020-03-23 | 一种治疗灰指甲的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010205271.6A CN111388529B (zh) | 2020-03-23 | 2020-03-23 | 一种治疗灰指甲的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111388529A CN111388529A (zh) | 2020-07-10 |
CN111388529B true CN111388529B (zh) | 2022-03-01 |
Family
ID=71416347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010205271.6A Active CN111388529B (zh) | 2020-03-23 | 2020-03-23 | 一种治疗灰指甲的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111388529B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105596577A (zh) * | 2016-01-05 | 2016-05-25 | 陈杏芬 | 一种治疗灰指甲的中药制剂及其制备方法和应用 |
CN108164524B (zh) * | 2017-12-12 | 2020-05-22 | 广东广发制药有限公司 | 一种黄藤素及提取方法、黄藤素胶囊及制备方法 |
-
2020
- 2020-03-23 CN CN202010205271.6A patent/CN111388529B/zh active Active
Non-Patent Citations (3)
Title |
---|
Fusarium as a cause of onychomycosis resistant to common antifungal therapy;Lysková P等;《Klinicka Mikrobiologie a Infekcni Lekarstvi》;20121201;第18卷(第6期);第184-191页 * |
汉麻叶的生物活性成分研究现状;何锦风等;《中国食品学报》;20111130;第11卷(第8期);第133-140页 * |
黄藤素溶解度的测定与关联;左文松等;《山东化工》;20121231;第41卷;第51-53页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111388529A (zh) | 2020-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2599028C2 (ru) | Растительный экстракт из конопли с низким содержанием тетрагидроканнабинола (тгк) для лечения заболеваний | |
US9993510B2 (en) | Acne-removing traditional chinese medicine composition and preparation method thereof | |
CN104688786A (zh) | 一种外用药物组合物及其制备方法和用途 | |
CN104922248B (zh) | 一种抗菌、消炎中药复方凝胶剂及制备方法 | |
CN102283899B (zh) | 一种中药外用制剂及其用途 | |
CN107496792B (zh) | 一种消炎抗菌治疗灰指甲的凝胶剂及其制备方法 | |
CN111388529B (zh) | 一种治疗灰指甲的药物组合物及其制备方法 | |
CN1251738C (zh) | 一种治疗灰指甲的中药及其制备方法 | |
CN114099632B (zh) | 一种中药发酵物及其在制备治疗真菌感染皮肤病药物上的应用 | |
CN105748545B (zh) | 一种三七根转化皂苷在制备抗真菌絮状表皮癣菌、红色毛癣菌、须毛癣菌药物方面的应用 | |
CN102973680B (zh) | 一种用于治疗浅部真菌感染的外用搽剂及其制备方法 | |
CN110051719B (zh) | 一种透骨草和侧柏叶混合提取物及其提取工艺与应用 | |
CN104288043B (zh) | 一种天然植物抗菌洗手液的制备方法 | |
CN107149641B (zh) | 一种用于治疗烧烫伤的组合物 | |
CN111388523A (zh) | 一种治疗痤疮的制剂及其制备方法 | |
CN101371889A (zh) | 一组治疗皮肤癣的药物配方及其制备方法 | |
CN110974932A (zh) | 防治真菌感染并具皮肤修复作用的中药组合物及制备方法 | |
CN104490970A (zh) | 一种治疗体癣的药物组合物及其制备方法 | |
CN110833584A (zh) | 一种凤仙花抑菌液及其制备方法 | |
CN1095377C (zh) | 治疗皮肤癣症、炎症的药物及其制备方法 | |
CN111437343B (zh) | 一种消炎止痛组合物和花红消炎止痛液及其制备方法 | |
TW201309317A (zh) | 一種用於治療傷口癒合的植物萃取物 | |
CN107362176B (zh) | 一种治疗灰指甲的组合物及其制备方法 | |
CN114652668A (zh) | 一种皮肤抑菌膏 | |
CN117018053A (zh) | 一种足部抗菌喷雾剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination for treating gray nails and its preparation method Effective date of registration: 20231225 Granted publication date: 20220301 Pledgee: Hua Xia Bank Co.,Ltd. Kunming Branch Pledgor: YUNNAN WEST GRASS RESOURCES DEVELOPMENT CO.,LTD. Registration number: Y2023980073832 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |